Responder analyses-A PhRMA position paper

Statistics in Biopharmaceutical Research

Volumn 3, Issue 3, 2011, Pages 476-487

  Uryniak, Tom ^a   Chan, Ivan S F ^b   Fedorov, Valerii V ^c   Jiang, Qi ^d   Oppenheimer, Leonard ^e   Snapinn, Steven M ^d   Teng, Chi Hse ^f   Zhang, John ^g  

^a ASTRAZENECA   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GLAXOSMITHKLINE   (United States)

^d AMGEN INC   (United States)

^e Statistical Science   (United States)

^f Statistics Amylin   (United States)

^g JOHNSON AND JOHNSON   (United States)

Author keywords

Clinical endpoint; Clinical meaningfulness of results; Dichotomization; Loss of power; Responders

Indexed keywords

ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; INFLUENZA; OUTCOME ASSESSMENT; POWER ANALYSIS; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; SAMPLE SIZE; STATISTICAL DISTRIBUTION; STATISTICAL SIGNIFICANCE; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; WEIGHT REDUCTION;

EID: 84867043433     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1198/sbr.2011.10070     Document Type: Article

References (26)

1. Altman, D. G., and Royston, P. (2006), "The Cost of Dichotomising Continuous Variables, " British Medical Journal, 332, 1080. 477
2. Campbell, M. J., Julious, S. A., and Altman, D. G. (1995), "Estimating Sample Sizes for Binary, Ordered Categorical, and Continuous Outcomes in 2 Group Comparisons, " British Medical Journal, 311, 1145-1148. 477
3. Deyi, B. A., Kosinski, A. S., and Snapinn, S. M. (1998), "Power Considerations When a Continuous Outcome Variable is Dichotomized, " Journal of Biopharmaceutical Statistics, 8, 337-352. 477
4. European Medicines Agency (CPMP/EWP/553/95) (1997), "Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease, " London, September 1997. Available online at http://www.ema.europa.eu/docs/en-GB/documentJibrary/Scientific-guideline/2009/09/WC500003562.pdf. 478
5. European Medicines Agency (CPMP/EWP/559/95) (1998a), "Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia, " London, February 26. Available online at http://www.ema.europa.eu/docs/en-GB/documentJibrary/ Scientific-guideline/2009/09/WC500003541.pdf. 478
6. European Medicines Agency (CPMP/EWP/563/95) (1998b), "Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Parkinson's Disease, " London, December 17. Available online at http://www.ema.europa.eu/docs/en-GB/documentJibrary/ Scientific-guideline/2009/09/WC500003540.pdf. 478
7. European Medicines Agency (CPMP/EWP/560/98) (2001), "Points to Consider on Clinical Investigation of Medicinal Products for the Treatment of Acute Stroke, " London, September 20. Available online at http://www.tga.gov.au/pdf/euguide/ewp056098en.pdf. 478
8. European Medicines Agency (CPMP/EWP/518/97) (2002a), "Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Depression, " London, April 25. Available online at http://www. ema.europa.eu/docs/ enGB/ document Jibrary/ Work-programme/2011/01/WC500100662.pdf. 478
9. European Medicines Agency (CPMP/EWP/1080/00) (2002b), "Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus, " London, May 30. Available online at http://www.ema.europa.eu/docs/ en-GB/documentlibrary/Scientific-guideline/2009/09/ WC500003262.pdf. 478
10. European Medicines Agency (CPMP/EWP/908/99) (2002c), "Points to Consider on Multiplicity Issues in Clinical Trials, " September 19. Available online at http://www.iscb.info/iscbdocs/emea-comments-Multiplicity.pdf. 478, 486
11. European Medicines Agency (CPMP/EWP/238/95) (2004), "Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Hypertension, " London, June 23. Available online at http://www.ema.europa.eu/docs/en-GB/documentJibrary/ Scientific-guideline/2009/09/WC500003375.pdf. 478
12. European Medicines Agency (CPMP/EWP/2158/99) (2005), "Guideline on the Choice of the Non-inferiority Margin, " London, July 27. Available online at http://www.ema.europa.eu/docs/enGB/ document Jibrary/Scientific-guideline/2009/09/ WC500003636. pdf. 477
13. European Medicines Agency (CPMP/EWP/281/96) (2007), "Guideline on Clinical Evaluation of Medical Products Used in Weight Control, " London, November 17. Available online at http://www. ema.europa.eu/docs/enGB/ documentJibrary/ Scientific-guideline/2009/09/WC500003213.pdf. 477, 478
14. FDA Draft Guidance for Industry (2006), "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, " 2006. 477, 483
15. FDA Guidance for Industry (1999), "Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA), " February 1999. Available online at http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM193282.pdf. 478
16. FDA Guidance for Industry (2005), "Systemic Lupus Erythematosus-Developing Drugs for Treatment, " March 2005. Available online at http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072063.pdf. 478
17. FDA Guidance for Industry (2007a), "Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, " May 2007a. Available online at http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ ucm074794.htm. 478
18. FDA Guidance for Industry (2007b) "Drug-Induced Liver Injury: Pre-marketing Clinical Evaluation, " October 2007b. Available online at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM174090.pdf. 477
19. Fedorov, V., Mannino, F., and Zhang, R. (2009), "Consequences of Di-chotomization, " Pharmaceutical Statistics, 8, 50-61. 479, 480, 481
20. Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., and Goldstein, R. S. (1998), "Interpreting Treatment Effects in Randomised Trials, " British Medical Journal, 316, 690-693. 477
21. International Conference on Harmonisation (1998), "Harmonized Tripartite Guideline Statistical Principles for Clinical Trials: E9, " February 5, 1998. Available online at http://www. ich.org/fileadmin/PublicWebSite/ICHProducts/ Guidelines/Efficacy/E9/Step4/E9-Guideline.pdf. 477
22. International Conference on Harmonisation E14 (2005), "Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs, " May 2005. Available online at http://www.fda.gov/RegulatoryInformation/Guidances/ ucm129335.htm. 478
23. Lewis, J. (2004), "In Defence of the Dichotomy, " Pharmaceutical Statistics, 4, 77-9. 477
24. Practice Guidelines For Primary Care Physicians (2003), "ESH/ESC Hypertension Guidelines. " Available online at http://www.ncbi.nlm. nih.gov/pubmed/14508180. 477
25. Senn, S. (2003), "Disappointing Dichotomies, " Pharmaceutical Statistics, 2, 239-240. 477
26. Snapinn, S., and Jiang, Q. (2007), "Responder Analyses and the Assessment of a Clinically Relevant Treatment Effect, " Current Controlled Trials in Cardiovascular Medicine, 8, 31. 477